Soligenix Reports $2.8 Million Net Loss in Q1 2026, Focuses on Product Development and Funding

Soligenix, Inc. reported a net loss of $2.8 million for the first quarter of 2026, a decrease from the $2.95 million loss recorded in the same period of 2025. The company did not generate any revenue during this quarter, consistent with the previous year. Operating expenses totaled $2.88 million, down from $3.03 million in the prior year, primarily due to reduced research and development costs, which fell to $1.78 million from $1.94 million. This reduction was attributed to lower expenses related to third-party manufacturing and the completion of a Phase 2 study, although it was partially offset by increased patient fees for ongoing clinical trials.

As of March 31, 2026, Soligenix had cash and cash equivalents of approximately $6.03 million, a decline from $7.94 million at the end of 2025. The company's working capital also decreased to $2.95 million from $5.15 million. The decrease in cash was primarily due to cash used in operating activities, although it was partially offset by proceeds from at-the-market sales of common stock. The company indicated that it has sufficient cash to support its operations into 2027 but raised concerns about its ability to continue as a going concern without securing additional capital.

In terms of strategic developments, Soligenix is focused on advancing its product candidates, including HyBryte™ for cutaneous T-cell lymphoma and SGX302 for psoriasis. The company is currently analyzing data from the interim efficacy analysis of the FLASH2 trial for HyBryte™, which was recommended to halt for futility. Additionally, Soligenix is pursuing additional funding through government grants and contracts, as well as potential equity offerings. The company has entered into a sales agreement with Rodman & Renshaw to sell shares of common stock, with approximately $0.8 million of potential gross proceeds remaining as of May 1, 2026.

Operationally, Soligenix's research and development efforts are concentrated on its Specialized BioTherapeutics and Public Health Solutions segments. The company is actively seeking partnerships and collaborations to enhance its pipeline and is exploring merger and acquisition opportunities. The total number of shares outstanding increased to 10.52 million as of March 31, 2026, from 10.09 million at the end of 2025, reflecting ongoing efforts to raise capital through equity sales. The company continues to face challenges in securing funding and achieving clinical milestones, which are critical for its long-term viability and growth.